Overview

A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF]

Status:
Unknown status

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

The investigators hypothesized that udenafil, a newly developed phosphodiesterase type 5 inhibitor, would improve symptom, exercise capacity and hemodynamic status in patients with heart failure with preserved ejection fraction (HFpEF).

Phase:

Phase 3

Details

Lead Sponsor:

Seoul National University Hospital

Collaborators:

Dong-A Pharmaceutical Co., Ltd.
Seoul National University Bundang Hospital

Treatments:

Udenafil